Driehaus Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-145,561
| Closed | -$20.6M | – | 414 |
|
|
2025
Q4 | $20.6M | Buy |
145,561
+40,599
| +39% | +$5.88M | 0.14% | 203 |
|
|
2025
Q3 | $14.7M | Buy |
+104,962
| New | +$14.2M | 0.11% | 230 |
|
|
2025
Q2 | – | Sell |
-108,547
| Closed | -$12M | – | 472 |
|
|
2025
Q1 | $12M | Buy |
108,547
+5,626
| +5% | +$713K | 0.12% | 218 |
|
|
2024
Q4 | $14M | Buy |
102,921
+32,114
| +45% | +$3.97M | 0.12% | 208 |
|
|
2024
Q3 | $8.16M | Sell |
70,807
-488
| -0.7% | -$66.9K | 0.07% | 246 |
|
|
2024
Q2 | $9.82M | Sell |
71,295
-294
| -0.4% | -$40.3K | 0.1% | 219 |
|
|
2024
Q1 | $9.87M | Sell |
71,589
-45,325
| -39% | -$6.19M | 0.1% | 235 |
|
|
2023
Q4 | $15.4M | Sell |
116,914
-76,568
| -40% | -$8.81M | 0.19% | 186 |
|
|
2023
Q3 | $21.8M | Buy |
193,482
+66,129
| +52% | +$6.96M | 0.28% | 115 |
|
|
2023
Q2 | $12M | Sell |
127,353
-64,924
| -34% | -$6.34M | 0.15% | 196 |
|
|
2023
Q1 | $19.5M | Sell |
192,277
-48,981
| -20% | -$5.1M | 0.27% | 119 |
|
|
2022
Q4 | $28.8M | Buy |
241,258
+18,601
| +8% | +$2.18M | 0.43% | 70 |
|
|
2022
Q3 | $23.6M | Buy |
222,657
+124,773
| +127% | +$12.7M | 0.36% | 89 |
|
|
2022
Q2 | $9.54M | Buy |
+97,884
| New | +$9.03M | 0.15% | 203 |
|
|
2020
Q3 | – | Sell |
-2,585
| Closed | -$315K | – | 430 |
|
|
2020
Q2 | $315K | Sell |
2,585
-4,389
| -63% | -$485K | 0.01% | 338 |
|
|
2020
Q1 | $604K | Sell |
6,974
-12,926
| -65% | -$1.27M | 0.02% | 289 |
|
|
2019
Q4 | $2.14M | Sell |
19,900
-11,577
| -37% | -$1.21M | 0.06% | 273 |
|
|
2019
Q3 | $2.84M | Buy |
+31,477
| New | +$2.94M | 0.09% | 217 |
|
|
2018
Q4 | – | Sell |
-17,893
| Closed | -$2.2M | – | 479 |
|
|
2018
Q3 | $2.2M | Buy |
17,893
+3,269
| +22% | +$371K | 0.07% | 272 |
|
|
2018
Q2 | $1.44M | Sell |
14,624
-1,839
| -11% | -$165K | 0.05% | 305 |
|
|
2018
Q1 | $1.36M | Buy |
16,463
+3,237
| +24% | +$273K | 0.05% | 306 |
|
|
2017
Q4 | $1.03M | Sell |
13,226
-1,074
| -8% | -$73.3K | 0.04% | 339 |
|
|
2017
Q3 | $876K | Buy |
+14,300
| New | +$755K | 0.03% | 335 |
|
|
2013
Q4 | – | Sell |
-78,764
| Closed | -$892K | – | 501 |
|
|
2013
Q3 | $892K | Sell |
78,764
-422,555
| -84% | -$5.81M | 0.03% | 361 |
|
|
2013
Q2 | $6.71M | Buy |
+501,319
| New | +$6.16M | 0.29% | 108 |
|
Other funds holding NBIX
Driehaus Capital Management's NBIX Position: Q1 2026 in Review
Driehaus Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 145,561 shares — an estimated $20.6M sold.
Driehaus Capital Management first reported a position in NBIX in Q2 2013 and held it in 25 quarters. The position peaked at $28.8M in Q4 2022. 697 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Driehaus Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
- Driehaus Capital Management sold 145,561 Neurocrine Biosciences shares in Q1 2026, an estimated $20.6M.
- Driehaus Capital Management first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 25 quarters.
- Driehaus Capital Management's Neurocrine Biosciences position peaked at $28.8M in Q4 2022.
- 697 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.